50
Participants
Start Date
August 31, 2009
Primary Completion Date
March 31, 2011
Study Completion Date
May 31, 2011
AlloStim-7
intradermal injection once a week for 3 weeks
percutaneous tumor cryoablation
ablation of a tumor by percutaneous cryoablation under CT guidance
AlloStim-7
intratumoral injection into cryoablated tumor lesion 1 hour after ablation
AlloStim8 or AlloStim-9
intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10\^8 cell dose and if no toxicity dose escalates to 10\^9 cell dose.
Immunovative Clinical Research, Inc, Carlsbad
Lead Sponsor
Mirror Biologics, Inc.
INDUSTRY